These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37327187)

  • 1. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.
    Gopal P; Robert ME; Zhang X
    Arch Pathol Lab Med; 2024 Mar; 148(3):359-370. PubMed ID: 37327187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches in search for biomarkers of cholangiocarcinoma.
    Mocan LP; Ilieș M; Melincovici CS; Spârchez M; Crăciun R; Nenu I; Horhat A; Tefas C; Spârchez Z; Iuga CA; Mocan T; Mihu CM
    World J Gastroenterol; 2022 Apr; 28(15):1508-1525. PubMed ID: 35582128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anatomical, histomorphological and molecular classification of cholangiocarcinoma.
    Kendall T; Verheij J; Gaudio E; Evert M; Guido M; Goeppert B; Carpino G
    Liver Int; 2019 May; 39 Suppl 1():7-18. PubMed ID: 30882996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholangiocarcinoma.
    Khan AS; Dageforde LA
    Surg Clin North Am; 2019 Apr; 99(2):315-335. PubMed ID: 30846037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.
    Walter D; Hartmann S; Waidmann O
    Z Gastroenterol; 2017 Jun; 55(6):575-581. PubMed ID: 28376540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholangiocarcinoma.
    Sarcognato S; Sacchi D; Fassan M; Fabris L; Cadamuro M; Zanus G; Cataldo I; Capelli P; Baciorri F; Cacciatore M; Guido M
    Pathologica; 2021 Jun; 113(3):158-169. PubMed ID: 34294934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy.
    Brown ZJ; Hewitt DB; Pawlik TM
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):85. PubMed ID: 35345317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.
    Goeppert B; Stichel D; Toth R; Fritzsche S; Loeffler MA; Schlitter AM; Neumann O; Assenov Y; Vogel MN; Mehrabi A; Hoffmann K; Köhler B; Springfeld C; Weichenhan D; Plass C; Esposito I; Schirmacher P; von Deimling A; Roessler S
    Gut; 2022 Feb; 71(2):391-401. PubMed ID: 33468537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholangiocarcinoma.
    Krasinskas AM
    Surg Pathol Clin; 2018 Jun; 11(2):403-429. PubMed ID: 29751883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
    Ilyas SI; Gores GJ
    Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical presentation, diagnosis and staging of cholangiocarcinoma.
    Forner A; Vidili G; Rengo M; Bujanda L; Ponz-Sarvisé M; Lamarca A
    Liver Int; 2019 May; 39 Suppl 1():98-107. PubMed ID: 30831002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
    Rimassa L; Personeni N; Aghemo A; Lleo A
    J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.
    European Association for the Study of the Liver
    J Hepatol; 2023 Jul; 79(1):181-208. PubMed ID: 37084797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the clinical diagnosis and therapy of cholangiocarcinoma.
    Yao D; Kunam VK; Li X
    J Int Med Res; 2014 Feb; 42(1):3-16. PubMed ID: 24366497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Angerilli V; Fornaro L; Pepe F; Rossi SM; Perrone G; Malapelle U; Fassan M
    Pathologica; 2023 Apr; 115(2):71-82. PubMed ID: 37017301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathology of Cholangiocarcinomas.
    Guedj N
    Curr Oncol; 2022 Dec; 30(1):370-380. PubMed ID: 36661679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
    Goeppert B
    Pathologe; 2020 Sep; 41(5):488-494. PubMed ID: 32757029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.